BACKGROUND: Conventional transarterial chemoembolization (cTACE) has been the standard treatment for intermediate stage hepatocellular carcinoma (HCC). For early stage HCC, percutaneous ablation is a curative option. There is growing evidence to support combined therapy to improve tumor response and overall survival (OS) in patients with unresectable HCC. The goal of this study is to retrospectively review a single institution patient population who underwent the combined approach to determine its efficacy and safety, and possible predictive factors for OS and tumor response. METHODS: Retrospective analysis identified all patients that underwent c-TACE with Mitomycin followed by percutaneous ablation from 2011 to 2016 at our institution. Efficacy was assessed by OS, time to progression (TTP), and tumor response according to mRECIST criteria. Initial imaging was obtained 1 month after each treatment and after complete response was achieved, every 3 months for 2 years. Percentage of Lipiodol uptake was determined at 30-day follow-up with contrasted abdominal CT. Safety was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Multiple linear regressions were conducted to predict OS and number of progression-free survival days based on potential predictive factors. RESULTS: A total of 50 patients were identified. At 1-month follow-up, objective response (CR + PR) was achieved in 44 patients (88%). The median OS was 26.6 months and median TTP was 9.7 months (n=50). There was no statistically significant difference in median OS between patients with different lesion size (P=0.95), BCLC stage (P=0.84) or Lipiodol uptake (P=0.36). Higher albumin/bilirubin ratio was significantly correlated with improved OS (P=0.024). CONCLUSIONS: Combined c-TACE and PTA is a safe and effective approach for patients with unresectable HCC. Elevated albumin/bilirubin ratio was a predictor for improved OS. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Conventional transarterial chemoembolization (cTACE) has been the standard treatment for intermediate stage hepatocellular carcinoma (HCC). For early stage HCC, percutaneous ablation is a curative option. There is growing evidence to support combined therapy to improve tumor response and overall survival (OS) in patients with unresectable HCC. The goal of this study is to retrospectively review a single institution patient population who underwent the combined approach to determine its efficacy and safety, and possible predictive factors for OS and tumor response. METHODS: Retrospective analysis identified all patients that underwent c-TACE with Mitomycin followed by percutaneous ablation from 2011 to 2016 at our institution. Efficacy was assessed by OS, time to progression (TTP), and tumor response according to mRECIST criteria. Initial imaging was obtained 1 month after each treatment and after complete response was achieved, every 3 months for 2 years. Percentage of Lipiodol uptake was determined at 30-day follow-up with contrasted abdominal CT. Safety was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Multiple linear regressions were conducted to predict OS and number of progression-free survival days based on potential predictive factors. RESULTS: A total of 50 patients were identified. At 1-month follow-up, objective response (CR + PR) was achieved in 44 patients (88%). The median OS was 26.6 months and median TTP was 9.7 months (n=50). There was no statistically significant difference in median OS between patients with different lesion size (P=0.95), BCLC stage (P=0.84) or Lipiodol uptake (P=0.36). Higher albumin/bilirubin ratio was significantly correlated with improved OS (P=0.024). CONCLUSIONS: Combined c-TACE and PTA is a safe and effective approach for patients with unresectable HCC. Elevated albumin/bilirubin ratio was a predictor for improved OS. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Daniel B Brown; Boris Nikolic; Anne M Covey; Charles W Nutting; Wael E A Saad; Riad Salem; Constantinos T Sofocleous; Daniel Y Sze Journal: J Vasc Interv Radiol Date: 2012-01-30 Impact factor: 3.464
Authors: K Takayasu; S Arii; N Matsuo; M Yoshikawa; M Ryu; K Takasaki; M Sato; N Yamanaka; Y Shimamura; M Ohto Journal: AJR Am J Roentgenol Date: 2000-09 Impact factor: 3.959
Authors: Andrea Veltri; Paolo Moretto; Andrea Doriguzzi; Eva Pagano; Giovanna Carrara; Giovanni Gandini Journal: Eur Radiol Date: 2005-10-14 Impact factor: 5.315
Authors: T de Baere; X Zhang; B Aubert; G Harry; C Lagrange; J Ropers; J Dufaux; J Lumbroso; P Rougier; M Ducreux; A Roche Journal: Radiology Date: 1996-12 Impact factor: 11.105
Authors: S Nahum Goldberg; Ihab R Kamel; Jonathan B Kruskal; Kevin Reynolds; Wayne L Monsky; Keith E Stuart; Muneeb Ahmed; Vassilos Raptopoulos Journal: AJR Am J Roentgenol Date: 2002-07 Impact factor: 3.959
Authors: Riccardo Lencioni; Thierry de Baere; Michael C Soulen; William S Rilling; Jean-Francois H Geschwind Journal: Hepatology Date: 2016-03-07 Impact factor: 17.425